Supplementary Table S3 from A pilot study of neoadjuvant nivolumab, ipilimumab and intralesional oncolytic virotherapy for HER2-negative breast cancer
Year: 2023
Type: supplementary-materials
Abstract: Individual details of baseline patient characteristics
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4385303531